Rare Daily Staff
Rare disease drug company Shire said it named Thomas Dittrich as its CFO and as a member of its board of directors.
He replaces Jeff Poulton, who in August announced he would step down at the end of the year to join the agbio startup Indigo Ag.
Dittrich, who is CFO of the global industrial engineering and manufacturing company Sulzer, will join Shire in early 2018 as he transitions out of his current position. Prior to Sulzer, Dittrich served as vice president, finance corporate planning and chief accounting officer at the biotech giant Amgen. He also spent four years as CFO of Amgen International.
Prior to working in biotechnology, he spent eight years with Dell in various finance and general manager roles. Earlier in his career he worked in consulting in both operational and merger and acquisition positions.
“Thomas’s wealth of experience while leading the finance teams at numerous multinational companies, including Amgen for several years, will be a tremendous asset for Shire as we continue to execute as the leading global biotech focused on rare diseases,” said Flemming Ornskov, CEO of Shire. “His unique financial skillset and results-oriented mentality make him the right person to lead Shire’s finance function.”
November 20, 2017